These success, together with a preceding report exhibiting that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like conduct in mice,2 help the strategy of targeting ACKR3 as a unique solution to modulate the opioid program, which could open new therapeutic avenues for opioid-similar disorders.Enhance much healthier immune function: Conol